anti-delta-like ligand 3 monoclonal antibody-drug conjugate

Anti-delta-like ligand 3 (DLL3) monoclonal antibody-drug conjugates (ADCs) are a class of targeted cancer therapeutics designed to treat neuroendocrine tumors, most notably small cell lung cancer (SCLC). DLL3 is an inhibitory Notch ligand that is highly overexpressed on the surface of tumor cells in approximately 80% of SCLC cases, while remaining largely absent in healthy adult tissues, making it an ideal target for ADC-based delivery. These agents consist of a humanized monoclonal antibody specific for DLL3, conjugated to a potent cytotoxic payload (such as a pyrrolobenzodiazepine dimer or a topoisomerase I inhibitor) via a linker. Upon binding to the extracellular domain of DLL3, the ADC is internalized through receptor-mediated endocytosis, followed by lysosomal degradation and the intracellular release of the payload, which induces DNA damage or mitotic arrest and subsequent apoptosis of the cancer cell.

Other names

anti-DLL3 ADCanti-DLL-3 ADCanti-DLL 3 ADCDLL3-targeted antibody-drug conjugateDLL-3-targeted antibody-drug conjugateDLL 3-targeted antibody-drug conjugateanti-delta-like ligand 3 monoclonal antibody-drug conjugate